Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 11/20 | 0.46 |
| ▸ | CTSB | P07858 | 5/20 | 0.46 |
| ▸ | CTSS | P25774 | 5/20 | 0.46 |
| ▸ | CTSK | P43235 | 8/20 | 0.44 |
| ▸ | CTSV | O60911 | 2/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.37 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.36 |
| ▸ | WNT3A | P56704 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6927425 | 0.88 | CTSL (0.55) | CTSLCTSBCTSSCTSKCTSV | |
| SCHEMBL7813767 | 0.87 | CTSL (0.43) | CTSLCTSBCTSSCTSKCTSV | |
| SCHEMBL7462272 | 0.86 | CTSL (0.50) | CTSLCTSBCTSSCTSKCTSV | |
| SCHEMBL7473345 | 0.86 | TAS1R3 (0.54) | CTSLCTSBCTSSCTSKCTSV | |
| SCHEMBL7473976 | 0.86 | CTSL (0.49) | CTSLCTSBCTSSCTSKCTSV | |
| SCHEMBL6927525 | 0.86 | CTSL (0.49) | CTSLCTSBCTSSCTSKCTSV | |
| SCHEMBL7467318 | 0.85 | CTSL (0.53) | CTSLCTSBCTSSCTSKCTSV | |
| SCHEMBL7461611 | 0.84 | CTSL (0.47) | CTSLCTSBCTSSCTSKCTSV | |
| SCHEMBL7466927 | 0.84 | CTSL (0.48) | CTSLCTSBCTSSCTSKTAS1R3 | |
| SCHEMBL7470718 | 0.84 | CTSL (0.51) | CTSLCTSBCTSSCTSKCTSV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020156018-A1 | Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamily | THOMPSON SCOTT KEVIN (US) | 2002-10-24 | — | — | US | claimed |
| US-20020156018-A1 | Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamily | THOMPSON SCOTT KEVIN (US) | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156018-A1 | Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamily | PEPD, PREP, CPN1 | CTSL 22/4885CTSB 35/4885CTSS 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.